Management of non-metastatic castrate-resistant prostate cancer: A systematic review

Yohann Loriot; Stéphane Supiot; Jean-Baptiste Beauval; Friederike Schlürmann; Gilles Pasticier; Paul Sargos; Philippe Barthélémy; Géraldine Pignot; Denis Maillet; Sébastien Vincendeau; Emmanuel Gross; Guillaume Ploussard; Marc-Olivier Timsit; Delphine Borchiellini

doi:10.1016/j.ctrv.2018.09.006

Management of non-metastatic castrate-resistant prostate cancer: A systematic review

Cancer Treat Rev. 2018 Nov:70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21.

Authors

Affiliations

¹ Medical Oncology Department, Gustave Roussy, Université Paris-Saclay, Paris, France. Electronic address: [email protected].
² Radiation Therapy Department, Institut de Cancérologie de L'Ouest René Gauducheau, Nantes St Herblain and Centre de Recherche en Cancérologie et Immunologie, Nantes-Angers, France.
³ Department of Urology, CHU Rangueil, Toulouse, France.
⁴ Medical Oncology Department, CHIC Quimper, France; CHRU Brest, Institut de Cancérologie et Hématologie, Brest, France.
⁵ Groupe Urologie Bordeaux Saint Gatien- Clinique TIVOLI-DUCOS, GROUPE SAINT GATIEN, Bordeaux, France.
⁶ Department of Radiation Therapy, Institut Bergonié, Bordeaux, France.
⁷ Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
⁸ Service de Chirurgie Oncologique 2, Institut Paoli-Calmettes, Marseille, France.
⁹ Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310 Pierre-Bénite, France.
¹⁰ Department of Urology, Rennes University Hospital, Rennes, France.
¹¹ Ramsay Générale de Santé, Hôpital Privé Clairval, Marseille, France.
¹² Department of Urology, Clinique La Croix du Sud-St Jean Languedoc, Toulouse, France, Institut Universitaire du Cancer, Toulouse, France.
¹³ Department of Urology, Hôpital européen Georges-Pompidou (HEGP), Assistance Publique-Hôpitaux de Paris (APHP), Paris, France; Paris-Descartes University, Paris, France.
¹⁴ Department of Oncology, Antoine-Lacassagne Center, Nice, France.

PMID: 30300771
DOI: 10.1016/j.ctrv.2018.09.006

Abstract

Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.

Keywords: Castration-resistant; Hormone therapies; Non-metastatic; Prostate cancer; nmCRPC.

Publication types

Review
Systematic Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Disease Management
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*

Substances

Antineoplastic Agents